Gastric ulcer treatment: Cure of Helicobacter pylori infection without subsequent acid-suppressive therapy: Is it effective?

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 6, 2008, Pages 489-491

  Van Zanten, Sander Veldhuyzen ^a   Van Der Knoop, Bloeme ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cure rate; Editorial; Gastric ulcer; Helicobacter; Peptic ulcer disease; Proton pump inhibitor; RCT; Ulcer recurrence

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; PROTON PUMP INHIBITOR;

CLINICAL TRIAL; DUODENUM ULCER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; STOMACH ULCER; TREATMENT DURATION; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMP INHIBITORS; STOMACH ULCER; TREATMENT OUTCOME;

EID: 43449136177     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f427c8     Document Type: Short Survey

References (11)

1. Veldhuyzen van Zanten SJO, Dixon M, Lee A. The gastric transitional zones: neglected links in gastric pathology and helicobacter ecology. Gastroenterology 1999; 116:1217-1229.
2. Sipponen P, Varis K, Fraki O, Korri UM, Seppala K, Siurala M. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients. Scand J Gastroenterol 1990; 25:966-973.
3. Baron JH. An assessment of the augmented histamine test in the diagnosis of peptic ulcer. Correlations between gastric secretion, age and sex of patients, and site and nature of the ulcer. Gut 1963; 4:243-253.
4. Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther 2005; 21:795-804.
5. Tulassay Z, Stolte M, Sjolund M, et al. Effect of esomeprazole triple therapy on Helicobacter pylori eradication rates, gastric ulcer healing, and prevention of relapse in gastric ulcer patients. Eur J Gastroeneterol Hepatol. 2008; 20:526-536.
6. Higuchi K, Fujiwara Y, Tominaga K, Watanabe T, Shiba M, Nakamura S, et al. Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment Pharmacol Ther 2003; 17:111-117.
7. Jones DB, Howden CW, Burget DW, Kerr GD, Hunt RH. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987; 28:1120-1127.
8. Hunt RH, Cederberg C, Dent J, Halter F, Howden C, Marks IN, et al. Optimizing acid suppression for treatment of acid-related diseases. Dig Dis Sci 1995; 40 (2 Suppl):24S-49S.
9. Veldhuyzen van Zanten SJO, Bradette M, Farley A, Leddin DJ, Bayerdorffer E, Lind T, et al. The DU-MACH Study. Eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13:289-295.
10. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15:1949-1958.
11. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14-22.